Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of Ralinepag XR in Healthy Chinese Subjects
NCT04613999Phase 1Completed
- Sponsor
- Everstar Medicines
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ralinepag in pulmonary arterial hypertension (PAH), sponsored by Everstar Medicines. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Concentration and 4 more. Started Oct 2020; status: completed.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04613999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04613999.